Patents by Inventor Henry Korman

Henry Korman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LPAR1 Inhibitors
    Publication number: 20260102383
    Abstract: Provided herein are compounds of Formula (I), compounds of Formula (II) and pharmaceutically acceptable salts thereof, useful as LPAR1 inhibitors, and pharmaceutical compositions comprising the same. Also provided are methods of treating or preventing a disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (II).
    Type: Application
    Filed: April 18, 2025
    Publication date: April 16, 2026
    Inventors: Henry Korman, Allan C. Krueger, Eric Breinlinger, Noel S. Wilson, Kyle R. Owens, Howard R. Heyman, James N. Newton, Anurupa Shrestha, Martin Garcia Chavez, Gang Zhao, Bo Liu, Daniel Hamza, Thomas D. Ackrill, Jayde A. McLellan, Alexander J. Leeder
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20240043386
    Abstract: The present invention provides for compounds of Formula (I) wherein R1 has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: October 10, 2023
    Publication date: February 8, 2024
    Inventors: Andrew Bogdan, David J. Hardee, Timothy R. Hodges, Henry Korman, Huan-Qiu Li, Michael R. Schrimpf
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20220213041
    Abstract: The present invention provides for compounds of Formula (I) wherein R1 has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: December 17, 2021
    Publication date: July 7, 2022
    Applicant: AbbVie Global Enterprises Ltd.
    Inventors: Andrew Bogdan, David J. Hardee, Timothy R. Hodges, Henry Korman, Huan-Qiu Li, Michael R. Schrimpf
  • 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto
    Patent number: 9676758
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of GPR52. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a GPR52-mediated disorder (e.g., Huntington's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD), or Tourette's syndrome); an extrapyramidal or movement disorder; a motor disorder; a hyperkinetic movement disorder; a psychotic disorder; catatonia; a mood disorder; a depressive disorder; an anxiety disorder; obsessive-compulsive disorder (OCD); an autism spectrum disorder; a prolactin-related disorder (e.g., hyperprolactinemia); a neurocognitive disorder; a trauma- or stressor-related disorder (e.g.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: June 13, 2017
    Assignee: Arena Pharmaceutical, Inc.
    Inventors: Yifeng Xiong, Andrew J. Grottick, Henry Korman, Juerg Lehmann, Albert S. Ren, Graeme Semple, Didier JC Bagnol
  • 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO
    Publication number: 20160318911
    Abstract: The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of GPR52. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a GPR52-mediated disorder (e.g., Huntington's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD), or Tourette's syndrome); an extrapyramidal or movement disorder; a motor disorder; a hyperkinetic movement disorder; a psychotic disorder; catatonia; a mood disorder; a depressive disorder; an anxiety disorder; obsessive-compulsive disorder (OCD); an autism spectrum disorder; a prolactin-related disorder (e.g., hyperprolactinemia); a neurocognitive disorder; a trauma- or stressor-related disorder (e.g.
    Type: Application
    Filed: April 29, 2016
    Publication date: November 3, 2016
    Applicant: Arena Pharmaceuticals, Inc.
    Inventors: Yifeng Xiong, Andrew J. Grottick, Henry Korman, Juerg Lehmann, Albert S. Ren, Graeme Semple